Uncertainty Looms Over Pfizer’s Oral COVID-19 Antiviral Pill – Doubts Over Commercial Approval
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla provided an update on the status of the company's oral antiviral COVID-19 treatment, Paxlovid, during his speech at the Cantor Fitzgerald Annual Healthcare Conference.